Aug 20 (Reuters) - Raptor Pharmaceutical Corp RPTP.O :
* Expands rare disease portfolio with the acquisition of Quinsair(TM)
* Under the terms of the agreement, Raptor will pay $68.4 million upfront
* Says reiterating its 2015 revenue guidance of $80 to $90 million
* Raptor will have single-digit contingent obligations to two additional
parties involved in quinsair's development
* Says Raptor plans to launch quinsair in Europe and Canada in the first half
of 2016
* Says up to $34.2 million of closing consideration payable in Raptor common
stock at raptor's election
* Says co will pay contingent payments of up to $350 million associated with
development, regulatory,commercial milestones
* Raptor is acquiring exclusive global rights and assets to develop,
manufacture and commercialize quinsair
* Source text for Eikon ID:nGNXVEGZDa
* Further company coverage RPTP.O